Sun Pharma Advanced Research Company Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SPARC.NS | SOLARA.NS | SUNPHARMA.BO | 001360.KS | 000230.KS | 1795.TW | |
|---|---|---|---|---|---|---|
| Market cap | 63.66B | 31.04B | 4.38T | 118.87B | 65.20B | 44.76B |
| P/E (TTM) | 3.9 | 83.4 | 40.1 | — | — | 11.8 |
| Forward P/E | 3.5 | 20.5 | 32.3 | — | — | 7.1 |
| Price/book | 4.8 | 2.2 | 5.6 | — | — | 1.9 |
| Dividend yield | — | — | 0.97% | — | 1.79% | 1.61% |
| 1-year change | +37.71% | +14.61% | −2.21% | −16.75% | −52.38% | −42.88% |
| Today | +5.84% | −0.25% | +2.78% | +0.08% | +0.89% | +5.66% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All SPARC.NS news ›Sun Pharma Advanced Research Wins CESTAT Ruling, Secures Rs 27.51 Cr CENVAT Refund
Mumbai: Sun Pharma Advanced Research Company Limited (SPARC) has won a litigation before the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai, with the Tribunal upholding the company's entitlement to a refund of…
More from 1 other outlet
Sun Pharma Advanced Research wins ₹28 crore CENVAT credit refund case in CESTAT
IndiaIPO Sun Pharma Advanced Research wins ₹28 crore CENVAT credit refund case in CESTAT Sun Pharma Advanced Research Company Ltd on Sunday said the Customs, Excise & Service Tax Appellate Tribunal , Mumbai, has upheld
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- businessupturn.com1
- indiaipo.in1
- medicaldialogues.in1
- scanx.trade1
- tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.